AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06357104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride
Description: Sertraline is taken in the morning for 150 mg per day.
Study NCT06357104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Clonazepam is taken in the morning for 1 mg per day.
Study NCT06357104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
Study NCT06357104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
Study NCT06357104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
Study NCT06357104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Sodium 20 MG
Description: Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
Study NCT06357104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril Valsartan Sodium Hydrate
Description: Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
Study NCT06570122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
Study NCT06570122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
Study NCT06570122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
Study NCT06570122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health warning leaflet
Description: The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
Study NCT06570122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-powered chatbot support
Description: Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
Study NCT04915716 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood glucose levels were monitored
Description: Peripheral blood glucose levels were monitored
Study NCT06430112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).
Study NCT06430112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
Study NCT05349058 — intervention group
Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: Patients receive Immune Checkpoint Inhibitor as per oncology protocol
Study NCT06350058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (low dose)
Description: The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.
Study NCT06350058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (high dose)
Description: The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.
Study NCT06178289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Cavilon Advanced Skin Protectant
Description: 3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
Study NCT04808778 — intervention group
Intervention type: DRUG
Intervention: Hydroxyurea therapy per standard care
Description: Moderate-dose of 20mg/kg/day
Study NCT05231408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic exercise training
Description: High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points.
Study NCT05231408 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
Study NCT06350058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Aluminum hydroxide adjuvant.
Study NCT05429177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin
Study NCT04853043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
Study NCT06106646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: No active intervention in this protocol (previously randomized to Vitamin C)
Description: In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
Study NCT06106646 — intervention group
Intervention type: OTHER
Intervention: No active intervention in this protocol (previously randomized to Placebo)
Description: In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
Study NCT06178289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hospital wound treatment protocol
Description: Comparator: Standard hospital wound treatment protocol
Study NCT06522880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMV PCR on saliva
Description: Observational study to measure prevalence of CMV shedding by saliva PCR
Study NCT05557903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
Description: Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
Study NCT06126666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL103
Description: ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Study NCT04956575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study NCT05356936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (MK-7)
Description: Participants will receive Vitamin K2 (MK-7) daily by mouth.
Study NCT05356936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants will receive Vitamin D3 daily by mouth.
Study NCT06525272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Chymotrypsin(OsrhCT)
Description: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.
Study NCT06525272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Recombinant Human Chymotrypsin(OsrhCT)
Description: Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.
Study NCT06343740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMET-Y
Description: Competitive memory training (COMET) is a transdiagnostic intervention first developed for adults and later adapted to be used in children and adolescents. The adapted version for youth consists of 7 sessions in which participants learn to facilitate activation of functional/positive thoughts instead of relying on dysfunctional/negative thoughts by using positive self-verbalizations, imagery, body posture, and music. In addition, they are challenged to reformulate dysfunctional/negative thoughts into more functional/positive thoughts. As an addition to the original COMET protocol, there is a parent session in which parents receive psycho-education about their influence on self-esteem. Parents learn to be a 'co-therapist' and to support practicing at home and improve generalization.
Study NCT05663567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solution oriented approach
Description: Implementing a solution-focused approach to support breastfeeding
Study NCT04751565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy
Description: Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
Study NCT06202430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Thoracic Erector Spinae Plane Block
Description: High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
Study NCT06202430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Block
Description: Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus.
Study NCT05316337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device
Study NCT05316337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with reference device
Study NCT04956575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride solution for injection
Study NCT04793763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional therapeutic exercises
Description: group A will receive traditional exercises
Study NCT04793763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapeutic exercises and McKenize technique
Description: Group B will receive traditional therapeutic exercises and McKenize technique
Study NCT04793763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapeutic exercises and deep neck flexor exercises
Description: Group C receive traditional therapeutic exercises and deep neck flexor exercises
Study NCT05833321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sarcopenia diagnostic test
Description: measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire
Study NCT05985382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Body Resistance Exercise
Description: Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
Study NCT04956575 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: 0.5 milliliter (mL) intramuscular (IM) injection
Study NCT04756830 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adsorbed COVID-19 (inactivated) Vaccine
Description: Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
Study NCT05985382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Body Resistance Exercise
Description: Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
Study NCT04740931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
Study NCT04740931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
Study NCT04740931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
Study NCT04740931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT04740931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT06467279 — intervention group
Intervention type: DEVICE
Intervention: Target Controlled İnfusion
Description: TCI (Target-Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
Study NCT06467279 — intervention group
Intervention type: DRUG
Intervention: Inhalation anesthetic
Description: In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
Study NCT05443269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jump Start Nutritional Program
Description: Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
Study NCT04798482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
Study NCT05385848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-rich Plasma (PRP) Injection
Description: PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
Study NCT05776680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: 60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
Study NCT06395870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LUCAR-G39D cells product
Description: Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
Study NCT04762459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily
Study NCT04762459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily
Study NCT04762459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) Pemetrexed
Study NCT04762459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) Pemetrexed
Study NCT04762459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
Study NCT04762459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
Study NCT04729465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol
Study NCT05094050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Continuous Subcutaneous Infusion (CSCI)
Study NCT04729465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol
Study NCT04729465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: Bispectral Index Monitor
Study NCT05009732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918
Description: 300mg once daily orally
Study NCT05047159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.
Study NCT05047159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy
Description: Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
Study NCT05047159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT
Description: The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
Study NCT05047159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MST
Description: A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
Study NCT05047159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy
Description: There is no restriction on the choice of therapeutic drugs.
Study NCT06484738 — intervention group
Intervention type: OTHER
Intervention: transcriptomic analysis
Description: to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ)
Description: Administered orally once daily